This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 50/6/1069    most recent HYPERTENSIONAHA.107.098806v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Elmarakby, A. A. Articles by Imig, J. D. Search for Related Content PubMed PubMed Citation Articles by Elmarakby, A. A. Articles by Imig, J. D. Related Collections Other hypertension Cardiovascular Pharmacology Other Treatment Growth factors/cytokines Hypertension - basic studies

(Hypertension. 2007;50:1069.)
© 2007 American Heart Association, Inc.

Original Articles

Chemokine Receptor 2b Inhibition Provides Renal Protection in Angiotensin II–Salt Hypertension

Ahmed A. Elmarakby; Jeffrey E. Quigley; Jeffrey J. Olearczyk; Aarthi Sridhar; Anthony K. Cook; Edward W. Inscho; David M. Pollock; John D. Imig

From the Departments of Physiology (A.K.C., E.W.I., D.M.P., J.D.I.) and Surgery (D.M.P.) and the Vascular Biology Center (A.A.E., J.E.Q., J.J.O., A.S., D.M.P., J.D.I.), Medical College of Georgia, Augusta.

Correspondence to John D. Imig, Vascular Biology Center, Medical College of Georgia, Augusta, GA 30912-2500. E-mail jdimig{at}mcg.edu

The present study was designed to determine whether chemokine receptor 2b (CCR2b) contributes to the development of renal injury in salt-sensitive angiotensin II (ANG) hypertension. Rats were infused with ANG and fed a high-salt diet (HS) for 14 days. Rats were divided into 4 groups: HS; HS administered the CCR2b antagonist, RS102895; Ang/HS hypertensive; and Ang/HS hypertensive administered RS102895. CCR2b inhibition slowed the progression of blood pressure elevation during the first week of ANG/HS hypertension; however, it did not alter blood pressure in the HS group. At 2 weeks, arterial pressure was not significantly different between ANG/HS and ANG/HS hypertensive rats administered RS102895. Renal cortical nuclear factor B activity increased in ANG/HS hypertension compared with the HS group (0.11±0.006 versus 0.08±0.003 ng of activated nuclear factor B per microgram of protein), and RS102895 treatment lowered nuclear factor B activity in ANG/HS hypertension (0.08±0.005 ng of activated nuclear factor B per microgram of protein). Renal tumor necrosis factor- and intercellular adhesion molecule-1 expression increased, and Cyp2c23 expression decreased in ANG/HS hypertension compared with the HS group, and CCR2b inhibition reduced tumor necrosis factor- and intercellular adhesion molecule-1 and increased Cyp2c23 expression. Histological immunostaining revealed increased renal monocyte and macrophage infiltration in ANG/HS hypertensive rats with decreased infiltration in rats receiving RS102895 treatment. Albuminuria and cortical collagen staining also increased in ANG/HS hypertensive rats, and RS102895 treatment lowered these effects. Afferent arteriolar autoregulatory responses to increasing renal perfusion pressure were blunted in ANG/HS hypertension, and RS102895 treatment improved this response. These data suggest that CCR2b inhibition protects the kidney in hypertension by reducing inflammation and delaying the progression of hypertension.

Key Words: kidney • inflammation • hypertension • angiotensin • MCP-1 • CCR2b • chemokines